Lumida
/KRRO
⌘K
Korro Bio Inc

Korro Bio Inc

KRRO
$13.81USD+5.74%+0.75 today

MARKET CAP

203.4M

P/E (TTM)

FWD P/E

DAY RANGE

$13 – $14

52W RANGE

$5
$56

AI Summary

Stalk
Buy NowMedium

KRRO has carved a Stage 1 base after a steep capitulation, enabling mean-reversion entries. The medium-term bias is bullish under mean-reversion eligibility and defined support. Recently, price has held a pullback into the rising 9/21/50-day EMA zone and prior consolidation highs, showing no short-term exhaustion. This presents a favorable entry on a supportive interaction. A breakdown below the EMA confluence and base support would invalidate this bullish posture.

  • HC Wainwright reiterates Buy rating with $15 price target.
  • CoinCodex projects 27.6% upside to $16.46 by end-2026.
  • Profitability metrics remain weak, reflecting poor return generation.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$2.3M$6.4M
YoY %+181.5%
P / Sales149.5x11.8x
EV / Sales154.0x18.1x
Gross Profit, Adj.$2.3M$6.4M
YoY %+181.5%
Margin %100.0%100.0%
EV / Gross Profit154.0x18.1x
EBITDA, Adj.$-88.3M$-83.1M
YoY %-9.2%+6.0%
Margin %-3890.1%-1299.5%
EV / EBITDA-4.0x-1.4x
EBIT$-91.9M$-121.9M
YoY %-8.7%-32.6%
Margin %-4047.1%-1906.4%
EV / EBIT-3.8x-0.9x
Net Income$-83.6M$-117.3M
YoY %-3.0%-40.3%
Net Margin-3680.4%-1834.5%
EPS (GAAP)-$9.37-$12.48
YoY %+82.3%-33.2%